Shs · CUSIP 24477V105 · who reports it, how much, and how much it matters to them
49 of the 720 hedge fund managers we track reported shares of Definium Therapeutics, Inc. (Nasdaq: DFTX) on Form 13F for 30 June 2026. Between them they reported USD 1.4bn. The largest position belongs to Avoro Capital Advisors, at USD 338m. The manager with the most riding on it is Octagon Capital Advisors, where it is 12.5% of the reported book.
Compiled from SEC Form 13F filings · Hedge Fund Intelligence, PPLI.com · updated
Form 13F is filed by the manager and covers all of its accounts, so a position here belongs to the firm, not to any one fund. Not investment advice.
A list of every manager in our coverage that reported this share at the end of the quarter, taken from the filings themselves. Short positions and options are not in it.
Taken from each manager's Form 13F for 30 June 2026. A manager appears here if it reported the shares themselves; positions held only through options are left out.
The bar and the percentage show how much of the manager's reported 13F book the position makes up. Each name opens that manager's largest fund on PPLI.com, where the rest of its book is listed.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Avoro Capital Advisors1 fund on PPLI.com | USD 338m | 3.0% |
| 2 | Octagon Capital Advisors1 fund on PPLI.com | USD 139m | 12.5% |
| 3 | Deep Track Capital1 fund on PPLI.com | USD 129m | 1.9% |
| 4 | Citadel Advisors32 funds on PPLI.com | USD 79m | 0.0% |
| 5 | Ra Capital Management1 fund on PPLI.com | USD 71m | 0.6% |
| 6 | Marshall Wace LLP84 funds on PPLI.com | USD 61m | 0.0% |
| 7 | Adage Capital Management1 fund on PPLI.com | USD 47m | 0.1% |
| 8 | Boxer Capital Management1 fund on PPLI.com | USD 47m | 3.5% |
| 9 | Two Sigma Investments35 funds on PPLI.com | USD 43m | 0.0% |
| 10 | Balyasny Asset Management25 funds on PPLI.com | USD 42m | 0.1% |
| 11 | Holocene Advisors2 funds on PPLI.com | USD 37m | 0.1% |
| 12 | Awm Investment Company6 funds on PPLI.com | USD 37m | 3.2% |
| 13 | Polar Capital LLP26 funds on PPLI.com | USD 37m | 0.1% |
| 14 | Arrowmark Colorado Holdings24 funds on PPLI.com | USD 27m | 1.1% |
| 15 | POINT72 Asset Management17 funds on PPLI.com | USD 23m | 0.0% |
| 16 | Great Point Partners2 funds on PPLI.com | USD 20m | 3.8% |
| 17 | Cormorant Asset Management1 fund on PPLI.com | USD 19m | 1.0% |
| 18 | RTW Investments2 funds on PPLI.com | USD 19m | 0.2% |
| 19 | Orbimed Advisors1 fund on PPLI.com | USD 17m | 0.3% |
| 20 | D. E. Shaw & Co.15 funds on PPLI.com | USD 15m | 0.0% |
| 21 | Millennium Management6 funds on PPLI.com | USD 13m | 0.0% |
| 22 | Sofinnova Investments1 fund on PPLI.com | USD 12m | 0.6% |
| 23 | PFM Health Sciences3 funds on PPLI.com | USD 12m | 1.0% |
| 24 | HighVista Strategies27 funds on PPLI.com | USD 11m | 2.6% |
| 25 | Eversept Partners3 funds on PPLI.com | USD 10m | 0.5% |
| 26 | Superstring Capital Management1 fund on PPLI.com | USD 8.9m | 5.6% |
| 27 | Brevan Howard Capital Management39 funds on PPLI.com | USD 7.4m | 0.1% |
| 28 | LMR Partners2 funds on PPLI.com | USD 7.1m | 0.0% |
| 29 | Rock Springs Capital Management2 funds on PPLI.com | USD 6.7m | 0.3% |
| 30 | Atika Capital Management3 funds on PPLI.com | USD 5.7m | 0.4% |
| 31 | Schonfeld Strategic Advisors30 funds on PPLI.com | USD 5.6m | 0.0% |
| 32 | Burkehill Global Management5 funds on PPLI.com | USD 4.7m | 0.2% |
| 33 | Logos Global Management1 fund on PPLI.com | USD 3.8m | 0.2% |
| 34 | Platinum Investment Management11 funds on PPLI.com | USD 3.3m | 0.8% |
| 35 | Atom Investors1 fund on PPLI.com | USD 2.3m | 0.2% |
| 36 | Polymer Capital Management (HK)1 fund on PPLI.com | USD 2.1m | 0.1% |
| 37 | Aquatic Capital Management3 funds on PPLI.com | USD 2m | 0.1% |
| 38 | Cinctive Capital Management5 funds on PPLI.com | USD 1.3m | 0.0% |
| 39 | Walleye Capital8 funds on PPLI.com | USD 971,000 | 0.0% |
| 40 | Persistent Asset Partners10 funds on PPLI.com | USD 648,000 | 0.2% |
| 41 | Fora Capital1 fund on PPLI.com | USD 629,000 | 0.0% |
| 42 | Engineers Gate Manager1 fund on PPLI.com | USD 481,000 | 0.0% |
| 43 | Capital Fund Management S.A.12 funds on PPLI.com | USD 476,000 | 0.0% |
| 44 | Mangrove Partners Im1 fund on PPLI.com | USD 427,000 | 0.0% |
| 45 | Entrypoint Capital1 fund on PPLI.com | USD 345,000 | 0.1% |
| 46 | Audent Global Asset Management3 funds on PPLI.com | USD 245,000 | 0.3% |
| 47 | Jain Global1 fund on PPLI.com | USD 234,000 | 0.0% |
| 48 | Neo Ivy Capital Management1 fund on PPLI.com | USD 14,817 | 0.0% |
| 49 | The Quarry1 fund on PPLI.com | USD 47 | 0.0% |
A large manager can hold a great deal of a share and barely notice it. This table turns the question round and ranks managers by how much of their own book the position takes up.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Octagon Capital Advisors | USD 139m | 12.5% |
| 2 | Superstring Capital Management | USD 8.9m | 5.6% |
| 3 | Great Point Partners | USD 20m | 3.8% |
| 4 | Boxer Capital Management | USD 47m | 3.5% |
| 5 | Awm Investment Company | USD 37m | 3.2% |
| 6 | Avoro Capital Advisors | USD 338m | 3.0% |
| 7 | HighVista Strategies | USD 11m | 2.6% |
| 8 | Deep Track Capital | USD 129m | 1.9% |
| 9 | Arrowmark Colorado Holdings | USD 27m | 1.1% |
| 10 | PFM Health Sciences | USD 12m | 1.0% |
Definium Therapeutics, Inc. trades under the symbol DFTX on the Nasdaq. Its CUSIP, the code used on Form 13F, is 24477V105.
49 of the 720 hedge fund managers PPLI.com tracks reported Definium Therapeutics, Inc. shares on Form 13F for 30 June 2026. The largest reported positions were held by Avoro Capital Advisors (USD 338m), Octagon Capital Advisors (USD 139m), Deep Track Capital (USD 129m), Citadel Advisors (USD 79m) and Ra Capital Management (USD 71m).
49 managers in our coverage reported it, and between them they run 462 funds with a file on PPLI.com. The count is of managers, because Form 13F is filed by the firm and not by each fund.
Octagon Capital Advisors, where the position was 12.5% of the reported 13F book at 30 June 2026.
No. Form 13F reports long positions in U.S.-listed shares and options. Short positions are not disclosed in it.
Positions are taken by PPLI.com from Form 13F filings with the U.S. Securities and Exchange Commission for the quarter shown. They are reported by each manager, cover all of its accounts and may have changed since. PPLI.com has no relationship with Definium Therapeutics, Inc. or with the managers listed.
Nothing here is investment, tax or legal advice, a recommendation, or an offer or solicitation to buy or sell any security. To report an error, write to the editor.
Read our Privacy Policy before submitting. Share only the information needed to describe your question; do not include medical records or account credentials.